The Alzheimer’s launch is growing—just not fast enough to satisfy a stock priced for a bolus, and a pharmacy data gap is making the slope harder to read.
AXSM · Earnings Call · 2026-11-02
Axsome’s 52% Quarter Meets a 43% Drawdown
The launch is working; the expectations aren’t
Axsome reported $260 million of Q3 revenue, up 52% year over year and 19% sequentially, with AUVELITY net product sales of $208 million and a GAAP net loss that narrowed to $12.9 million from $47.2 million a year ago. On the numbers alone, this was the kind of quarter that should have stabilized a stock. Instead, the shares are down roughly 43% over the last 90 days and about 44% from their June peak. The disconnect is the Alzheimer’s disease agitation launch: investors wanted a bolus; management is delivering a curve.
The analyst question was blunt:
it seems that it has not met investors' expectation with the stock down 40% to 45% since the launch has started.
Management did not flinch. Ari Maizel pointed to patients 65 and older, where new-to-brand prescriptions grew 211% year over year and 99% sequentially, and total prescriptions rose 101% and 43%. Total prescriptions across the portfolio reached about 302,000, up 40% year over year. Those are strong percentages, but they are off a small base and against a market that grew only 3%.
What changed: from “ready to go” to “still educating”
The prior calls framed ADA as a launch that could scale quickly. In February, management said it would be “ready to go within a quarter on ADA” — Ari Maizel, Chief Commercial Officer · 2026-02-23 and that “70%+ scripts for ADA will be written in the Medicare Part D channel” — Nick Pizzie, Chief Financial Officer · 2026-02-23, with a more favorable gross-to-net than commercial. By May, the company had raised AUVELITY’s peak-sales estimate to at least $8 billion. The current call keeps the $8 billion number but changes the tone: “this is still a relatively new and developing market” — Ari Maizel, Chief Commercial Officer · 2026-11-02, with significant education required on agitation symptoms and diagnosis.
That is not a nothingburger. It means the ADA opportunity is real but back-end loaded, and the market is repricing the slope, not the size. The company says long-term care is performing in line with the 65+ cohort, but the sales cycle is longer. “LTC as a channel is performing well thus far with growth rates that are similar to what we reported for patients 65 and older” — Ari Maizel, Chief Commercial Officer · 2026-11-02, Ari said, while acknowledging the multiple stakeholders and longer facility cycles. Primary care is now nearly 40% of prescribers and 25% of prescriptions—good breadth, but also a sign that the launch is still in the activation phase.
Coverage is not the bottleneck. AUVELITY has about 89% total lives covered, including 82% commercial and roughly 100% in the government channel. Management has worked to remove prior authorizations and says abandonment is not out of the ordinary, even if Medicare abandonment runs higher than commercial. The new worry is the Advantage plans shuffle: analysts asked whether plan closures could disrupt access; Ari said there has been no disruption so far.
The data-quality fog
The most company-specific new keyword on this call is capture rate. Nick Pizzie disclosed that IQVIA’s capture rate appeared to drop to around 90%, potentially because new pharmacies were added with the ADA launch, and that a pharmacy chain stopped reporting scripts to one data provider in October. “a pharmacy chain stopped reporting scripts in October. To 1 of the data providers, which may also be impacting the TRxs or NBRx” — Nick Pizzie, Chief Financial Officer · 2026-11-02. That is the kind of disclosure that makes investors reach for the aspirin. In a launch where the sell side is already debating the slope, a third-party data distortion is rocket fuel for bear cases.
It also explains why management leaned so hard on its own leading indicators: new-to-brand prescriptions, new prescriber activation, and the 65+ cohort. The total prescriptions number is still the scoreboard, but the company is asking investors to trust NBRx as the leading signal. That is reasonable—NBRx leads TRx—but it is also a narrative shift from “look at the revenue” to “look through the data noise.”
The pipeline is the new alibi—and the next catalyst
With the ADA launch no longer a slam dunk, management spent more time on the pipeline. The call laid out a 2027 catalyst stack: AXS-12 for cataplexy has a PDUFA date of May 1, 2027; solriamfetol in binge eating disorder has top-line data in Q1 2027; ADHD pediatric studies read out in H2 2027; AXS-14 in fibromyalgia completes enrollment in Q3 2027; and AXS-20 in schizophrenia is slated to start Phase III in H1 2027.
The CEO also spent unusual airtime on placebo response, a new emphasis in the Q3 keyword set. “placebo response is something that we think about quite a lot as we design all of our studies” — Herriot Tabuteau, Chief Executive Officer · 2026-11-02, Herriot Tabuteau said, describing proprietary “bells and whistles” to mitigate it. That is a tell: the next big value driver is a schizophrenia trial where the market has learned to discount high placebo response. Management is pre-emptively framing its trial design.
The pipeline is genuinely deep, but it is also 2027-heavy. The near-term stock debate will remain tied to AUVELITY’s ADA conversion and the credibility of the company’s script data. The label expansion story is still the core; the pipeline is the option value.
Fundamentals: operating leverage is real, valuation is still full
The fundamental trajectory supports management’s operating-leverage claim. Total revenue was $218 million in the last filed quarter, up 46% year over year, and the just-reported Q3 reached $260 million. The GAAP loss is narrowing: net loss was $51 million in the last filed quarter, versus $12.9 million in Q3. Cash ended the quarter at $314 million, which management says funds operations to cash-flow positivity.
But the valuation is still not cheap. Price to revenue was 16.5x in the last filed data, up 57% year over year even as the stock has fallen. That is the crux: the company has to grow into the multiple, and the ADA launch is the main bridge. If the launch cadence slips, the multiple has room to compress; if it reaccelerates, the drawdown is an opportunity.
Management declined to guide Q4 or 2027. “we do not give specific guidance on for Q4 or for 2027” — Nick Pizzie, Chief Financial Officer · 2026-11-02, Nick said, pointing instead to sequential NBRx growth and refill conversion. That is defensible for a launch, but it leaves investors with third-party data and a lot of inference.
What to watch
Three things matter from here. First, Q4 AUVELITY net sales and the gross-to-net bridge: management expects GTN to tick up slightly on Q4 accruals, so the revenue quality matters as much as the top line. Second, the script data: if the pharmacy-chain reporting gap persists, the market will distrust the weekly numbers and punish any wobble. Third, the 2027 readouts: AXS-12’s PDUFA and the binge-eating data are the nearest catalysts, but the schizophrenia Phase III start is the one that could reset the long-term narrative.
The stock is not down because the quarter was bad. It is down because the quarter was good enough to keep the $8 billion promise alive but not good enough to prove the ADA launch is on a straight line. Axsome now has to do the unglamorous work: convert education into prescriptions, convert prescriptions into paid packs, and convert a 2027 pipeline into credible milestones. The market will believe the revenue when the data stops needing an asterisk.